An enzyme called MICAL2 promotes tumor growth and metastasis in the most common form of pancreatic cancer, according to a new study.

The Whipple procedure, which removes part of the pancreas, intestine and gallbladder, is the standard for pancreatic cancer.

Pancreatic cancer is one of the most lethal malignancies, with nearly 50,000 deaths annually in the United States, according ...

Pancreatic cancer kills 50,000 people each year, according to the National Cancer Institute, and there are few effective ...

Pancreatic cancer screening has advanced significantly in recent years. There are now research-based guidelines on screening ...

Researchers at UC San Diego have discovered that the enzyme MICAL2 accelerates tumor growth in pancreatic cancer by ...

The FDA approved several drugs in December for the treatment of diseases including pancreatic adenocarcinoma, lung cancer, ...

The disease is rarely found in time for lifesaving treatment, and kills about half a million people annually; here is what to ...

In its pursuit of a cancer drug for pancreatic cancer and possibly ovarian cancer, Amplia has history on its side.

Pancreatic cancer has a poor prognosis accounting for a 5-year overall survival rate lower than 10%. This proportion could reach about one-third of patients ...

Gedatolisib is under clinical development by Celcuity and currently in Phase I for Pancreatic Cancer. According to GlobalData, Phase I drugs for Pancreatic Cancer have a 74% phase transition success ...